Oppenheimer & Co. Inc. Lowers Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oppenheimer & Co. Inc. cut its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 18,345 shares of the medical equipment provider’s stock after selling 720 shares during the period. Oppenheimer & Co. Inc.’s holdings in Intuitive Surgical were worth $9,012,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Oppenheimer Asset Management Inc. increased its position in shares of Intuitive Surgical by 2.0% in the third quarter. Oppenheimer Asset Management Inc. now owns 56,155 shares of the medical equipment provider’s stock valued at $27,587,000 after buying an additional 1,122 shares in the last quarter. Pinnacle Financial Partners Inc lifted its position in shares of Intuitive Surgical by 4.5% during the 3rd quarter. Pinnacle Financial Partners Inc now owns 22,492 shares of the medical equipment provider’s stock valued at $11,050,000 after buying an additional 972 shares in the last quarter. MQS Management LLC acquired a new stake in Intuitive Surgical in the 3rd quarter valued at $411,000. Souders Financial Advisors increased its holdings in Intuitive Surgical by 218.5% in the 3rd quarter. Souders Financial Advisors now owns 3,236 shares of the medical equipment provider’s stock worth $1,590,000 after acquiring an additional 2,220 shares in the last quarter. Finally, Dillon & Associates Inc. raised its position in Intuitive Surgical by 1.2% during the third quarter. Dillon & Associates Inc. now owns 24,274 shares of the medical equipment provider’s stock worth $11,919,000 after acquiring an additional 277 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity

In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 396 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $486.88, for a total transaction of $192,804.48. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,680,761.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 91,178 shares of company stock valued at $45,897,071 in the last quarter. Insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

ISRG has been the topic of several research analyst reports. Mizuho lifted their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Royal Bank of Canada increased their target price on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday, October 18th. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Finally, Citigroup boosted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $536.69 on Thursday. The company’s 50-day moving average is $495.85 and its two-hundred day moving average is $455.08. Intuitive Surgical, Inc. has a 1-year low of $287.98 and a 1-year high of $542.59. The firm has a market capitalization of $191.16 billion, a price-to-earnings ratio of 86.28, a PEG ratio of 5.28 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.